Jaguar Health, Inc. (JAGX) earnings
JAGX earnings moved a median of +0.42% by the close. Quarterly and annual JAGX reports and results, each read against the price at its own news timestamp. Back to the JAGX overview →
29 measured JAGX earnings events.
Where these JAGX earnings landedvs 29 measured JAGX earnings reactions
| Middle 50% of JAGX earnings reactions | -4.46% to +2.96% |
|---|---|
| Median reaction (to close) | +0.42% |
| Measured reactions | 29 |
Point-in-time · zero look-ahead
Half of the 29 JAGX earnings events with a measured close landed between -4.46% and +2.96%; 62% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Jaguar Health, Inc. For: Jun 30 | SEC filing · Form 10-Q | — | -4.20% | |
| Jaguar Health Reports Second Quarter 2026 Financials | Press release | -4.56% | +0.40% | |
| Form NT 10-Q Jaguar Health, Inc. For: Jun 30 | SEC filing · Form NT | -2.50% | -2.34% | |
| Form 10-Q Jaguar Health, Inc. For: Mar 31 | SEC filing · Form 10-Q | +16.78% | +11.94% | |
| Jaguar Health Reports First Quarter 2026 Financials | Press release | +16.78% | +11.94% | |
| Form NT 10-Q Jaguar Health, Inc. For: Mar 31 | SEC filing · Form NT | +1.29% | -4.64% | |
| Form 10-K Jaguar Health, Inc. For: Dec 31 | SEC filing · Form 10-K | +1.78% | +4.12% | |
| Form NT 10-K Jaguar Health, Inc. For: Dec 31 | SEC filing · Form NT | -0.62% | +2.96% | |
| Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue | Press release | +0.00% | +1.98% | |
| Form 10-Q Jaguar Health, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +1.98% | |
| Form 10-Q Jaguar Health, Inc. For: Jun 30 | SEC filing · Form 10-Q | -3.03% | -10.39% | |
| Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue | Press release | -3.03% | -10.39% | |
| Form 10-Q Jaguar Health, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.20% | +0.20% | |
| Jaguar Health Reports First Quarter 2025 Financials | Press release | +1.12% | +2.42% | |
| Form 10-K/A Jaguar Health, Inc. For: Dec 31 | SEC filing · Form 10-K | +2.93% | +9.60% | |
| Form 10-K Jaguar Health, Inc. For: Dec 31 | SEC filing · Form 10-K | -0.41% | -3.25% | |
| Form 10-Q Jaguar Health, Inc. For: Sep 30 | SEC filing · Form 10-Q | +1.11% | -12.60% | |
| Jaguar Health Reports Third Quarter 2024 Financial Results | Press release | +1.11% | -12.60% | |
| Form 10-Q Jaguar Health, Inc. For: Jun 30 | SEC filing · Form 10-Q | -9.82% | -4.46% | |
| Jaguar Health Reports Second Quarter 2024 Financial Results | Press release | -9.82% | -4.46% | |
| REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients | Press release | +0.86% | +3.45% | |
| Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial’s Clinically Meaningful | Press release | +0.95% | +0.86% | |
| Form 10-Q Jaguar Health, Inc. For: Mar 31 | SEC filing · Form 10-Q | +3.70% | +1.78% | |
| Jaguar Health Reports First Quarter 2024 Financial Results | Press release | +3.70% | +1.78% | |
| Form 10-K/A Jaguar Health, Inc. For: Dec 31 | SEC filing · Form 10-K | +8.60% | +22.82% | |
| Form 10-K Jaguar Health, Inc. For: Dec 31 | SEC filing · Form 10-K | -14.24% | -14.35% | |
| FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS | Press release | -2.97% | +12.27% | |
| Form 10-Q Jaguar Health, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.88% | +0.42% | |
| Jaguar Health Reports Third Quarter 2023 Financial Results | Press release | +0.88% | +0.42% |
Keep exploring
More JAGX: analyst actions → · SEC filings → · JAGX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CareDx, Inc. (CDNA) | 443 | -0.11% | 47% |
| Arvinas, Inc. (ARVN) | 442 | -0.26% | 42% |
| BOVIE MEDICAL (BVX) | 441 | 0.00% | 46% |
| Catalyst Pharmaceuticals, Inc. (CPRX) | 441 | 0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.